top of page

Pipeline Overview

Nanodose Therapeutics is committed to advancing its nanodosed recombinant proteins to develop life-enhancing medicines for people suffering from chronic debilitating conditions.
 
Our pipeline is focused in four areas:

  • Chronic Traumatic Brain Injury

  • Alzheimer's Disease

  • Stroke

  • hypermobile Ehlers-Danlos Syndrome

Candidate
Description
Target Indication
Lead
Generation
Lead Optimization
IND
Enabling
IND
Phase I
Phase II
Phase III
IND Submission planned for August 2024
With oSLO IND clearance & Phase I results, programs ready to enter Phase II 
bottom of page